LY 4167586
Alternative Names: LY-4167586Latest Information Update: 28 Nov 2025
At a glance
- Originator Eli Lilly and Company
- Class Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 06 Nov 2025 Preclinical trials in Obesity in USA (IV)
- 06 Nov 2025 Preclinical trials in Obesity in USA (SC)
- 06 Nov 2025 Eli Lilly and Company plans a phase I trial for Obesity (In volunteers) in the USA and Singapore (IV,SC) in November 2025 (NCT07225556)